SanBio (4592) · FactRestated
SB623 designated as an advanced therapy medicinal product (ATMP) by the European Medicines Agency
First written in FY2020-Q1. 2 of 3 entries say "Restated". Latest entry: FY2020.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
SB623's European ATMP designation and global expansionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「In Europe, SB623 was designated as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency (EMA) in April 2019」
SB623's ATMP designation by the EMA has been reconfirmed as a regulatory development toward global expansion, including in Europe. - FY2020-Q3RestatedAnnual report
「In Europe, SB623 was designated as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency (EMA) in April 2019」
SB623's ATMP designation by the EMA has been reconfirmed as a regulatory development toward global expansion, including in Europe. - FY2020-Q1First statedAnnual report
「In April 2019, regenerative cell therapy SB623 was also designated as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency (EMA).」
SB623's ATMP designation by the EMA in April 2019 is described as a new regulatory development toward global expansion in Europe.